Remoxy slated for mid-2010 resubmission

Needing time to gather data on the stability of their experimental pain med Remoxy, King Pharmaceuticals and Pain Therapeutics say they may have to wait until mid-2010 to resubmit their marketing application. The FDA snubbed the developers in December. Shares for both companies slid on the news of the delay. Release l Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.